Please login to the form below
morphosys
This page shows the latest morphosys news and features for those working in and with pharma, biotech and healthcare.
CHMP recommends eight new medicines for EU approval
The CHMP also adopted a positive opinion for MorphoSys and Incyte’s Monjuvi (tafasitamab) for the treatment of relapsed or refractory diffuse B-cell lymphoma (DLBCL) for patients who are not ... MorphoSys. The CHMP has also recommended approval of
Latest news
-
MorphoSys expands oncology pipeline with $1.7bn acquisition of Constellation Pharmaceuticals
MorphoSys has also entered into a long-term strategic funding partnership with Royalty Pharma. ... The funds will be used to support MorphoSys’ acquisition of Constellation, as well as the development of the combined pipeline.
-
Incyte signs lymphoma deal worth up to $1.1bn with MorphoSys
Under the terms of the deal, Incyte is paying MorphoSys $750m upfront, as well as making an equity investment worth $150m in the company. ... MorphoSys is also eligible to receive milestone payments worth up to $1.1bn, in addition to any royalties from
-
J&J’s new Darzalex formulation OK’d for use in Europe
More competition could also come from MorphoSys and Takeda, which both have anti-CD38 drugs in late-stage studies for myeloma.
-
MorphoSys drops Novartis-partnered drug in eczema after phase 2 miss
Therapy candidate was licensed in a $1bn-plus deal last year. Germany’s MorphoSys has abandoned an atopic dermatitis drug licensed by Novartis in a $1bn-plus deal last year after ... The decision to drop MOR106, a selective IL-17c inhibitor
-
FDA verdict on Sanofi’s Darzalex rival is due in April 2020
Additional competition is however looming from MorphoSys and Takeda, which each have anti-CD38 drugs in pivotal-stage testing for myeloma, while another rival is Bristol-Myers Squibb and AbbVie’s
More from news
Approximately 6 fully matching, plus 18 partially matching documents found.
Latest Intelligence
-
European biotech: a new generation of leaders emerges
Morphosys. One of Europe’s star performers over the last two to three years has been Germany’s Morphosys. ... Unlike many other European biotechs, Morphosys isn’t seeking a marketing partner for the launch of its lead product, and aims to go it
-
Deal Watch November 2016
acquisition - company. 125+. MorphoSys/ Leo Pharma. discovery and development of mAbs for skin diseases.
-
Pharma deals in March 2015
In the same area is Morphosys which has been less fortunate this month because of the termination of its $818m agreement with Celgene to develop a Mab for treatment of multiple ... myeloma. Morphosys' share price fell by over 20%. This is an
-
Deal Watch table for August 2014
187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).
-
Pharma deals during August 2014
These include the usual sprinkling of small molecule (Millennium/ Infinity, Hanmi/ Luye, Ziopharm/ Solasia) and antibody (Emergent/ Morphosys) approaches but also more alternative approaches as exemplified by the Gamida/ Novartis agreement.
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest appointments
-
Pharma industry appointments
Lemus was also chief executive officer of Sigma Tau Pharmaceuticals and chief financial officer and executive vice president of MorphoSys, where he took the company public in 1999.
-
Robert Freisen joins Ablynx
He has previously held roles for ProQR Therapeutics, Janssen BioTherapeutics, and MorphoSys.
-
Dave Lemus joins Proteros as an executive board member
He has also held roles with MorphoSys and Hoffman La Roche.
-
MorphoSys appoints Dr Markus Enzelberger as CSO
He succeeds Dr Marlies Sproll who resigns. German biotech MorphoSys has appointed Dr Markus Enzelberger as its new chief scientific officer following his predecessor, Dr Marlies Sproll’s resignation. ... Dr Gerald Moller, supervisory board chairman,
-
MC Services welcomes Dr Claudia Gutjahr-Loeser to its management team
She joins the PR firm from MorphoSys, where she was senior VP. ... She joins the Duesseldorf, Germany-based firm from MorphoSys, where she headed the corporate communications and investor relations department as senior vice president; a role that saw her
More from appointments
Approximately 3 fully matching, plus 6 partially matching documents found.
Subscribe to our email news alerts
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- AstraZeneca’s mild combination asthma reliever approved in UK
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis
- Positive results for Almirall’s lebrikizumab in atopic dermatitis published in NEJM and BJD
- When to call in the specialists: strategy in Medical Affairs
- Time to talk about health inequalities
- Powering Rapid Cognitive Analysis with AI
- AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis
- Positive results for Almirall’s lebrikizumab in atopic dermatitis published in NEJM and BJD
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Janssen’s single tablet combination shows promise in phase 3 PAH study
- How to make sure your adverts for clinical trials are compliant
PMHub
Thrive Agency
We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...
Latest intelligence
- Time to talk about health inequalities
- Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
